Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
The study highlights the importance of adjusting rifampicin dosing to achieve therapeutic levels in patients with coinfection. Doubling rifampicin dosing in patients with HIV-TB coinfection increases the percentage of patients with Cmax within the therapeutic range. Additionally, while EFV slightly affects rifampicin and isoniazid PK, these changes are not clinically significant, supporting the efficacy and safety of the combined regimen.
Authors
- Elisabeth Baudin (ORCID: https://orcid.org/0000-0002-6575-6971)
- Maryline Bonnet (ORCID: https://orcid.org/0000-0002-1071-7393)
- Racheal Kyohairwe
- Christophe Michon
- Laurent Arthur Decosterd (ORCID: https://orcid.org/0000-0002-9840-1325)
- Dan Nyehangane (ORCID: https://orcid.org/0000-0002-1898-4162)
- Keneth Kananura
- Helen McIlleron (ORCID: https://orcid.org/0000-0002-0982-6226)
- Bruno Falissard (ORCID: https://orcid.org/0000-0002-2418-4954)
- Amina Jindani (ORCID: https://orcid.org/0000-0002-7110-5286)
- Deborah Nanjebe (ORCID: https://orcid.org/0000-0002-5440-7100)
- Grace Muzanye
- Thomas S. Harrison (ORCID: https://orcid.org/0000-0003-3619-4348)
- Thibaut Gelé (ORCID: https://orcid.org/0000-0002-7366-9499)
- Pauline Justumus
- Alexandra Calmy
- F.–X. Blanc (ORCID: https://orcid.org/0000-0001-7644-2188)
- Winnie R. Muyindike (ORCID: https://orcid.org/0000-0002-6694-2645)
- Daniel Atwine
- Kenneth Mworozi
- Aurélie Barrail‐Tran (ORCID: https://orcid.org/0000-0002-6053-6275)
- Susan Logoose
- Valérie Furlan
- A M Taburet
- Y Mendy
Institutions
- Mbarara University of Science and Technology (UG)
- Inserm (FR)
- Université de Montpellier (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Mbarara National Referral Hospital (UG)
- CEA Paris-Saclay - Etablissement de Fontenay-aux-roses (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Epicentre Uganda (UG)
- CEA Paris-Saclay (FR)
- Infectious Disease Models and Innovative Therapies (FR)
- Bicêtre Hospital (FR)
- Médecins Sans Frontières (FR)
- Institut de Recherche pour le Développement (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1093/jac/dkaf319
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Médecins Sans Frontières
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales